Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis

被引:87
作者
Battle, TE
Lynch, RA
Frank, DA
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1158/0008-5472.CAN-05-3612
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the role of the transcription factor signal transducer and activator of transcription (STAT) 1 on endothelial cell function, human umbilical vein endothelial cells (HUVEC) were treated with IFN-gamma, a potent activator of STAT1. IFN-gamma inhibited cell growth and tube formation of HUVECs. Although the potent proangiogenic protein vascular endothelial growth factor (VEGF) stimulated cell growth and tube formation, IFN-gamma could suppress these effects of VEGF. Transfection of HUVECs with short interfering RNA targeting STAT1 abrogated IFN-gamma-induced inhibition of HUVEC growth and tube formation, and suppressed the inhibition of VEGF-induced tube formation by IFN-gamma, indicating that STAT1 is critical for this process. IFN-gamma blocks the biological activity of VEGF through inhibition of genes necessary for the VEGF response, including angiopoietin-2, urokinase plasminogen activator, tissue inhibitor of matrix metalloproteinase-1, cyclooxygenase-2, and VEGF receptor 2. To extend these findings in vivo, the role of STAT1 in angiogenesis was examined in STAT1-deficient mice using the Matrigel in vivo angiogenesis assay. Substantial cellular infiltration and formation of vascular structures occurred in STAT1-/- mice compared with wild-type controls. These data indicate that STAT1 plays a key role in the inhibition of angiogenesis through its action within endothelial cells, and exploiting this process may be useful in treating cancers and vascular tumors.
引用
收藏
页码:3649 / 3657
页数:9
相关论文
共 51 条
[1]   Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene [J].
Alexander, CM ;
Howard, EW ;
Bissell, MJ ;
Werb, Z .
JOURNAL OF CELL BIOLOGY, 1996, 135 (06) :1669-1677
[2]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[3]  
2-Z
[4]   A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12 [J].
Angiolillo, AL ;
Sgadari, C ;
Tosato, G .
INERLEUKIN 12: CELLULAR AND MOLECULAR IMMUNOLOGY OF AN IMPORTANT REGULATORY CYTOKINE, 1996, 795 :158-167
[5]   PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4 [J].
Arora, T ;
Liu, B ;
He, HC ;
Kim, J ;
Murphy, TL ;
Murphy, KM ;
Modlin, RL ;
Shuai, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (24) :21327-21330
[6]   INTERFERON-GAMMA FOR THE TREATMENT OF METASTATIC RENAL-CANCER - DOSE-DEPENDENT STIMULATION AND DOWN-REGULATION OF BETA-2 MICROGLOBULIN AND NEOPTERIN RESPONSES [J].
AULITZKY, W ;
GASTL, G ;
AULITZKY, WE ;
NACHBAUR, K ;
LANSKE, B ;
KEMMLER, G ;
FLENER, R ;
FRICK, J ;
HUBER, C .
IMMUNOBIOLOGY, 1987, 176 (1-2) :85-95
[7]  
Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
[8]   STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1 [J].
Battle, TE ;
Frank, DA .
BLOOD, 2003, 102 (08) :3016-3024
[9]  
Battle TE, 2003, CLIN CANCER RES, V9, P2166
[10]   How tumors become angiogenic [J].
Bouck, N ;
Stellmach, V ;
Hsu, SC .
ADVANCES IN CANCER RESEARCH, VOL 69, 1996, 69 :135-174